; (B) prescription drug compounding services; and (C) home infusion therapy services. (3) An analysis of affected beneficiaries and their use of the TRICARE Pharmacy program under TPharm4 and TPharm5, including: (A) Data on affected beneficiaries’ use of MTF pharmacies, TRICARE mail order program, Accredo, departed retail pharmacies, network retail pharmacies. (B) An assessment of medication compliance rates for affected beneficiaries for the three years prior to October 24, 2022, compared to the period-to-date following October 24, 2022. (C) Data on affected beneficiaries’ use of pharmacies that offer long-term care services, compound pharmacies, home infusion therapy. (D) The number of affected beneficiaries and number of total TRICARE beneficiaries by age group: under age 18, 18–24, 25–44, 45–64, 65–79, 80 and older. (4) An analysis on the effect on long-term care residents under TPharm4 and TPharm5, including: (A) The number of beneficiaries who filled at least one prescription at a pharmacy that provides long-term care services. (B) The number of beneficiaries who filled prescriptions at a single long-term care pharmacy only with no prescriptions filled via mail order, MTF pharmacy, or another retail pharmacy. (5) An analysis of non-network pharmacy use by TRICARE beneficiaries under TPharm4 and TPharm5, disaggregated by rural beneficiaries, non-rural beneficiaries, affected beneficiaries, rural affected beneficiaries, and non-rural affected beneficiaries: (A) The number of beneficiaries who used a non-network pharmacy. (B) The number of non-network claims submitted. (C) For all non-network claims submitted— (i) the average TRICARE allowed amount per prescription; (ii) the average TRICARE amount paid per prescription